Welcome to our dedicated page for Haemonetics Corporation news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Corporation stock.
Haemonetics Corporation (NYSE: HAE) is a global leader in blood management solutions, dedicated to improving patient care and reducing healthcare costs. The company offers a comprehensive portfolio of integrated devices, information management systems, and consulting services that address every facet of blood and plasma management. Haemonetics operates through three key segments: Plasma, Blood Center, and Hospital.
In the Plasma segment, Haemonetics focuses on providing innovative technologies for plasma collection and processing. The company's products help ensure a steady supply of high-quality plasma for the production of biopharmaceuticals and other therapeutic applications.
Within the Blood Center segment, Haemonetics offers advanced solutions for blood component collection and processing, aiding in the optimization of blood supply chains. Despite facing high competition in this segment, the company continues to innovate and enhance its product offerings.
The Hospital segment is a significant growth area for Haemonetics, providing essential tools for surgical suites and transfusion services. The company's technologies help prevent unnecessary blood transfusions and ensure the right blood product is used at the right time, improving patient outcomes.
Recently, Haemonetics has achieved several milestones, including the acquisition of Attune Medical, the manufacturer of the FDA-cleared ensoETM® esophageal cooling device. This acquisition strengthens Haemonetics' presence in the electrophysiology market and complements its vascular closure offerings.
Haemonetics also received 510(k) clearance from the U.S. FDA for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge, expanding its capabilities to serve fully heparinized patients in critical surgical procedures.
The company's financial performance remains robust, with a strong focus on revenue growth and strategic investments. Haemonetics continues to explore new markets and develop cutting-edge technologies to stay at the forefront of the healthcare industry.
To stay updated with the latest developments and financial results, Haemonetics regularly hosts investor calls and webcasts, providing transparency and insights into its ongoing projects and future plans.
Haemonetics Corporation (NYSE: HAE) announced the appointment of James C. D'Arecca as Executive Vice President and Chief Financial Officer, effective April 11, 2022. D'Arecca succeeds William P. Burke, who will remain in an advisory role until June 30, 2022. D'Arecca brings nearly 30 years of experience in finance leadership from companies like TherapeuticsMD and Allergan. His role will include overseeing treasury, tax, and financial planning, critical for Haemonetics' growth objectives. The appointment aims to strengthen the financial strategy and enhance stakeholder value.
Haemonetics Corporation (NYSE: HAE) announced that CEO Chris Simon will engage in a fireside chat with investors at the Raymond James 43rd Annual Institutional Investors Conference on March 7, 2022, at 9:50 a.m. ET. Interested individuals can access a live webcast through Haemonetics' Investor Relations website, and a replay will be available 12 hours post-event for a year. Haemonetics focuses on innovative healthcare solutions to enhance patient care and reduce costs, particularly in blood and plasma collection, surgical operations, and transfusion services.
Haemonetics Corporation (NYSE: HAE) announced its third quarter fiscal 2022 financial results, concluding on January 1, 2022. The details are accessible on its Investor Relations website. A conference call will take place on February 8, 2022, at 8:00 a.m. EST to discuss these results, with a live webcast and replay available for a year. Haemonetics specializes in innovative medical products and solutions aimed at enhancing patient care and reducing healthcare costs across blood and plasma collection, surgical suites, and hospital transfusion services.
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2022 financial results on February 8, 2022, at 6:00 am EST. A conference call will be held at 8:00 am EST the same day, where executives will discuss the results and respond to questions. Investors can access the call via a toll-free number or participate through a live webcast on the company's investor relations website. A replay will be available for one year from the call's conclusion.
Haemonetics Corporation (NYSE: HAE) released its financial results for Q2 FY22, ending October 2, 2021. The results are now available on their Investor Relations website. A conference call is scheduled for November 9, 2021, at 8:00 a.m. EST to discuss these results, accessible via a toll-free number and a live webcast. The earnings release and analytical tables have been posted online for investor review. For more details, visit their website.
Haemonetics Corporation (NYSE: HAE) announced the upcoming retirement of CFO William P. Burke, effective June 30, 2022. Burke, who joined the company in 2016, will assist in the transition to his successor. CEO Chris Simon acknowledged Burke's significant contributions to the company’s turnaround and strategic financial initiatives that have fostered long-term growth. Burke expressed his pride in the company's finance team and confidence in Haemonetics' future direction.
Haemonetics Corporation (NYSE: HAE) announced the release date for its second quarter fiscal year 2022 financial results, which is set for 6:00 am EST on November 9, 2021. The company will conduct a conference call at 8:00 am EST on the same day to discuss the results with investors and analysts. Participants can access the call via a toll-free number or an international line, with a conference ID of 3529538. A replay of the call will be available for one year starting November 9, 2021 at 11:00 a.m. EST.
Haemonetics Corporation (NYSE: HAE) announced that its VASCADE MVP® Venous Vascular Closure System is the first and only FDA-approved device for same-day discharge after atrial fibrillation (AF) ablation. This approval follows the successful completion of clinical studies showing that 99.4% to 99.6% of patients were discharged the same day without complications. The VASCADE MVP aims to enhance patient outcomes and care efficiency, which is crucial in the current healthcare landscape accelerated by COVID-19. The company is also poised to enroll patients for further studies in 2022.
Haemonetics Corporation (NYSE: HAE) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 9, 2021, at 8:45 a.m. ET. Chris Simon, the President and CEO, will lead the presentation, which can be accessed live via webcast at Morgan Stanley's website. Haemonetics focuses on innovative medical products that improve patient care and lower healthcare costs, particularly in blood and plasma component collection, surgical suites, and hospital transfusion services. More information can be found on their official website.
Haemonetics Corporation (NYSE: HAE) announced that the financial results for its first quarter of fiscal 2022, ending July 3, 2021, are now available on its Investor Relations website. A conference call is scheduled for August 11, 2021, at 8:00 a.m. ET to discuss these results, with access details provided. The company emphasized its commitment to improving patient care through innovative medical solutions. Further information is accessible via their investor portal.
FAQ
What is the current stock price of Haemonetics Corporation (HAE)?
What is the market cap of Haemonetics Corporation (HAE)?
What does Haemonetics Corporation specialize in?
What are the main segments of Haemonetics' business?
What recent acquisitions has Haemonetics made?
What is the TEG® 6s hemostasis analyzer system?
How does Haemonetics support its plasma segment?
What are the financial highlights of Haemonetics?
How does Haemonetics improve patient care?
What was the significance of the FDA clearance for Haemonetics?
What is Haemonetics' approach to innovation?
How can investors stay updated on Haemonetics' performance?
